Amgen (AMGN) Operating Income (2009 - 2026)
Amgen (AMGN) posted quarterly Operating Income of $2.7 billion for Q1 2026, up 126.32% year-over-year from $1.2 billion in Q1 2025, and down 1.99% quarter-over-quarter from $2.7 billion in Q4 2025.
Amgen (AMGN) Operating Income (2009 - 2026) Analysis & Trends
Amgen's Operating Income history runs 18 years deep, the most recent figure standing at $2.7 billion for Q1 2026.
- In Q1 2026, Operating Income rose 126.32% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $10.6 billion (up 41.95% YoY), while the FY2025 annual figure was $9.1 billion, up 25.1% from the prior year.
- Operating Income for Q1 2026 stood at $2.7 billion, down from $2.7 billion in the prior quarter.
- The five-year high for Operating Income was $2.7 billion in Q4 2025, with the low at $991.0 million in Q1 2024.
- The 5-year median for Operating Income is $2.2 billion (2022), against an average of $2.1 billion.
- The sharpest annual moves came in 2022 and 2024: Operating Income soared 162.8% in 2022, then slumped 48.41% in 2024.
- Amgen's Operating Income stood at $2.2 billion in 2022, then plunged by 43.0% to $1.3 billion in 2023, then surged by 81.83% to $2.3 billion in 2024, then increased by 17.7% to $2.7 billion in 2025, then fell by 1.99% to $2.7 billion in 2026.
- Business Quant data shows AMGN's Operating Income at $2.7 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.77 Bn | 632.01 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 469.90 Bn | 463.33 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 377.04 Bn | 369.90 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 303.08 Bn | 295.39 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 257.74 Bn | 252.84 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 236.46 Bn | 222.47 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 181.81 Bn | 178.63 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 106.28 Bn | 102.11 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Sanofi | 55.01 Bn | 47.63 Bn | 10.79 Bn | 16.77 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.51 Bn |
| Mar 31, 2026 | 2.67 Bn |
| Dec 31, 2025 | 2.72 Bn |
| Sep 30, 2025 | 2.53 Bn |
| Jun 30, 2025 | 2.66 Bn |
| Mar 31, 2025 | 1.18 Bn |
| Dec 31, 2024 | 2.31 Bn |
| Sep 30, 2024 | 2.05 Bn |
| Jun 30, 2024 | 1.91 Bn |
| Mar 31, 2024 | 991.00 Mn |
| Dec 31, 2023 | 1.27 Bn |
| Sep 30, 2023 | 2.02 Bn |
| Jun 30, 2023 | 2.68 Bn |
| Mar 31, 2023 | 1.92 Bn |
| Dec 31, 2022 | 2.23 Bn |
| Sep 30, 2022 | 2.66 Bn |
| Jun 30, 2022 | 2.18 Bn |
| Mar 31, 2022 | 2.50 Bn |
| Dec 31, 2021 | 2.30 Bn |
| Sep 30, 2021 | 2.38 Bn |